MX2021012848A - Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn. - Google Patents

Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn.

Info

Publication number
MX2021012848A
MX2021012848A MX2021012848A MX2021012848A MX2021012848A MX 2021012848 A MX2021012848 A MX 2021012848A MX 2021012848 A MX2021012848 A MX 2021012848A MX 2021012848 A MX2021012848 A MX 2021012848A MX 2021012848 A MX2021012848 A MX 2021012848A
Authority
MX
Mexico
Prior art keywords
disease
treatment
crohn
mirikizumab
antibody
Prior art date
Application number
MX2021012848A
Other languages
English (en)
Spanish (es)
Inventor
Jay Lawrence Tuttle
Stuart William Friedrich
Paul Frederick Pollack
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2021012848A publication Critical patent/MX2021012848A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2021012848A 2019-04-22 2020-04-15 Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn. MX2021012848A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836910P 2019-04-22 2019-04-22
PCT/US2020/028273 WO2020219314A1 (en) 2019-04-22 2020-04-15 Mirikizumab for use in a method of treating crohn's disease

Publications (1)

Publication Number Publication Date
MX2021012848A true MX2021012848A (es) 2021-12-10

Family

ID=70554215

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012848A MX2021012848A (es) 2019-04-22 2020-04-15 Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn.

Country Status (21)

Country Link
US (1) US20220040299A1 (enExample)
EP (3) EP3958897B1 (enExample)
JP (3) JP7297930B2 (enExample)
KR (2) KR20250153865A (enExample)
CN (2) CN119700968A (enExample)
AU (2) AU2020263238C1 (enExample)
BR (1) BR112021018930A2 (enExample)
DK (1) DK3958897T3 (enExample)
EA (1) EA202192532A1 (enExample)
ES (1) ES3075314T3 (enExample)
FI (1) FI3958897T3 (enExample)
IL (2) IL286818B2 (enExample)
LT (1) LT3958897T (enExample)
MA (1) MA55756A (enExample)
MX (1) MX2021012848A (enExample)
PT (1) PT3958897T (enExample)
SG (1) SG11202110619XA (enExample)
TW (2) TWI850365B (enExample)
UA (1) UA128657C2 (enExample)
WO (1) WO2020219314A1 (enExample)
ZA (1) ZA202108094B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
KR20220066831A (ko) 2020-11-16 2022-05-24 엔브이에이치코리아(주) 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
US20160031983A1 (en) 2013-03-15 2016-02-04 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
TWI811716B (zh) * 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
WO2018035330A1 (en) * 2016-08-19 2018-02-22 Janssen Biotech, Inc. Methods of treating crohn's disease with an anti-nkg2d antibody
EP3652539A4 (en) * 2017-07-10 2021-03-31 Rambam Med-Tech Ltd. ASSAYS FOR EVALUATING NEUTRALIZING ANTIBODIES IN ORGANIC MEDICINE TREATED PATIENTS AND USES THEREOF IN PERSONALIZED MEDICINE
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法

Also Published As

Publication number Publication date
CN113677366A (zh) 2021-11-19
BR112021018930A2 (pt) 2022-01-18
EP3958897A1 (en) 2022-03-02
JP7761614B2 (ja) 2025-10-28
ZA202108094B (en) 2025-05-28
TW202515610A (zh) 2025-04-16
AU2020263238B2 (en) 2023-08-17
AU2020263238C1 (en) 2024-02-22
WO2020219314A1 (en) 2020-10-29
EP4778573A2 (en) 2026-07-22
TWI850365B (zh) 2024-08-01
CN119700968A (zh) 2025-03-28
EP3958897B1 (en) 2026-05-06
PT3958897T (pt) 2026-07-17
KR20250153865A (ko) 2025-10-27
AU2020263238A1 (en) 2021-11-04
SG11202110619XA (en) 2021-11-29
IL286818A (en) 2021-10-31
EA202192532A1 (ru) 2022-01-21
JP2025148449A (ja) 2025-10-07
EP4789714A2 (en) 2026-08-12
UA128657C2 (uk) 2024-09-18
KR102869852B1 (ko) 2025-10-14
NZ781127A (en) 2025-06-27
DK3958897T3 (da) 2026-07-20
JP7297930B2 (ja) 2023-06-26
US20220040299A1 (en) 2022-02-10
TW202103734A (zh) 2021-02-01
LT3958897T (lt) 2026-08-10
AU2023265759A1 (en) 2023-12-07
JP2023116680A (ja) 2023-08-22
ES3075314T3 (en) 2026-08-03
FI3958897T3 (fi) 2026-07-16
IL286818B1 (en) 2025-11-01
KR20210142704A (ko) 2021-11-25
MA55756A (fr) 2022-03-02
IL286818B2 (en) 2026-03-01
JP2022530397A (ja) 2022-06-29
CA3134587A1 (en) 2020-10-29
IL324048A (en) 2025-12-01

Similar Documents

Publication Publication Date Title
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
MX2021002322A (es) Nuevos metodos.
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
ZA202005388B (en) Methods of treating ulcerative colitis
MX2018012076A (es) Composiciones y anticuerpos anti proteina 3 que contiene inmunoglobulina de linfocitos t y el dominio de mucina (tim-3).
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
UY37456A (es) Inmunoglobulinas y sus usos
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
EA202190708A1 (ru) Модуляторы экспрессии pnpla3
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX385589B (es) RÉGIMEN DE DOSIFICACIÓN PARA ANTAGONISTAS DE MAdCAM.
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
EA201991736A1 (ru) Антитело против оболочечного herv-k и его применение
MX390157B (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
MX2023007405A (es) Regimen de cladribina para usarse en el tratamiento de formas progresivas de esclerosis multiple.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
MX2017009929A (es) Composiciones y métodos para metabolismo muscular mejorado.
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
MX2017013879A (es) Composiciones que comprenden anakinra.
EA202192532A1 (ru) Мирикизумаб для применения в способе лечения болезни крона
EA201990768A1 (ru) Оптимизированные синтетические консенсусные иммуногенные композиции, нацеленные на белок активации фибробластов